| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
196.93(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,622 |
| 52
Week Range: |
$1.32 - $4.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 5.2 |
| Insider 3/6 Months : 9.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,500 |
4,000 |
5,598 |
32,898 |
| Total Buy Value |
$10,840 |
$11,733 |
$14,587 |
$57,671 |
| Total People Bought |
2 |
3 |
3 |
5 |
| Total Buy Transactions |
2 |
3 |
4 |
11 |
| Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
| Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lewis Joel |
President and CEO |
• • – |
2022-08-31 |
4 |
A |
$1.90 |
$17,501 |
D/D |
9,211 |
596,405 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-08-15 |
4 |
A |
$2.18 |
$17,501 |
D/D |
8,028 |
587,194 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-07-29 |
4/A |
A |
$2.26 |
$17,499 |
D/D |
7,743 |
552,139 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-07-29 |
4 |
A |
$2.26 |
$23,970 |
D/D |
10,606 |
552,139 |
|
- |
|
| Zordani Richard A. Jr. |
|
• • – |
2022-07-28 |
4 |
B |
$2.50 |
$12,500 |
D/D |
5,000 |
29,583 |
0.01 |
-53% |
|
| 10x Fund, L.p. |
10% Owner |
– – • |
2022-07-27 |
4/A |
AS |
$2.09 |
$20,870 |
D/D |
(10,000) |
6,168,940 |
|
- |
|
| Czirr James C |
Director |
– • • |
2022-07-22 |
4 |
AS |
$2.09 |
$20,870 |
D/D |
(10,000) |
6,168,940 |
|
-34% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-07-15 |
4 |
A |
$1.65 |
$17,500 |
D/D |
10,606 |
544,396 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-06-30 |
4 |
A |
$1.31 |
$17,500 |
D/D |
13,359 |
533,790 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-06-15 |
4 |
A |
$1.29 |
$17,776 |
D/D |
13,780 |
520,431 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-05-31 |
4 |
A |
$1.29 |
$17,500 |
D/D |
13,566 |
506,651 |
|
- |
|
| Freeman Kevin D |
|
• • – |
2022-05-19 |
4 |
B |
$1.33 |
$6,650 |
I/I |
5,000 |
65,000 |
0.01 |
25% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-05-13 |
4 |
A |
$1.36 |
$17,500 |
D/D |
12,868 |
493,085 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-04-29 |
4 |
A |
$1.55 |
$17,500 |
D/D |
11,290 |
480,217 |
|
- |
|
| Freeman Kevin D |
|
• • – |
2022-04-18 |
4 |
B |
$1.71 |
$8,550 |
I/I |
5,000 |
60,000 |
0.01 |
18% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-04-15 |
4 |
A |
$1.74 |
$17,499 |
D/D |
10,057 |
468,927 |
|
- |
|
| Zordani Richard A. Jr. |
|
• • – |
2022-04-04 |
4 |
B |
$1.61 |
$8,025 |
D/D |
5,000 |
24,583 |
0.01 |
29% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-03-31 |
4 |
A |
$1.61 |
$17,501 |
D/D |
10,870 |
458,870 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-03-15 |
4 |
A |
$1.74 |
$17,499 |
D/D |
10,057 |
448,000 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-02-28 |
4 |
A |
$1.87 |
$17,499 |
D/D |
9,358 |
438 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-02-15 |
4 |
A |
$2.07 |
$17,500 |
D/D |
8,454 |
428,585 |
|
- |
|
| Czirr James C |
Director |
– • • |
2022-02-02 |
4 |
AS |
$2.10 |
$21,000 |
D/D |
(10,000) |
6,178,940 |
|
-39% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-01-31 |
4 |
A |
$1.93 |
$216,668 |
D/D |
112,263 |
420,131 |
|
- |
|
| Uihlein Richard E |
|
• • • |
2022-01-24 |
4 |
A |
$1.98 |
$35,000 |
D/D |
17,677 |
7,936,677 |
|
- |
|
| Schwartz Elissa J. |
|
• • – |
2022-01-21 |
4 |
B |
$2.00 |
$2,000 |
D/D |
1,000 |
1,000 |
0.01 |
-16% |
|
516 Records found
|
|
Page 3 of 21 |
|
|
0.05 (1.43%) 
